BTIG Research Reiterates “Buy” Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reissued by equities research analysts at BTIG Research in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $8.00 target price on the stock. BTIG Research’s target price would suggest a potential upside of 222.71% from the stock’s current price.

Several other analysts also recently weighed in on ACIU. Weiss Ratings restated a “sell (e+)” rating on shares of AC Immune in a research report on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating on shares of AC Immune in a research report on Wednesday, July 1st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $7.50.

AC Immune Price Performance

Shares of NASDAQ:ACIU traded down $0.10 during midday trading on Thursday, hitting $2.48. The stock had a trading volume of 54,844 shares, compared to its average volume of 287,669. The company has a quick ratio of 1.02, a current ratio of 0.93 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $252.29 million, a P/E ratio of -4.60 and a beta of 1.59. The company’s 50-day moving average price is $2.40 and its 200-day moving average price is $2.71. AC Immune has a fifty-two week low of $2.03 and a fifty-two week high of $4.00.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.13. The business had revenue of $18.67 million during the quarter, compared to the consensus estimate of $9.59 million. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. As a group, equities research analysts predict that AC Immune will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ACIU. Arrowstreet Capital Limited Partnership increased its position in shares of AC Immune by 8.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after acquiring an additional 30,035 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after purchasing an additional 176,701 shares in the last quarter. EFG International AG bought a new position in AC Immune in the 4th quarter valued at approximately $41,000. Marshall Wace LLP bought a new stake in AC Immune in the 4th quarter worth about $586,000. Finally, Goldman Sachs Group Inc. grew its stake in shares of AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after acquiring an additional 5,920 shares during the period. 51.36% of the stock is owned by institutional investors.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.